CL2019000766A1 - Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantes. - Google Patents

Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantes.

Info

Publication number
CL2019000766A1
CL2019000766A1 CL2019000766A CL2019000766A CL2019000766A1 CL 2019000766 A1 CL2019000766 A1 CL 2019000766A1 CL 2019000766 A CL2019000766 A CL 2019000766A CL 2019000766 A CL2019000766 A CL 2019000766A CL 2019000766 A1 CL2019000766 A1 CL 2019000766A1
Authority
CL
Chile
Prior art keywords
stabilizing
methods
lipoic acid
choline ester
ester compositions
Prior art date
Application number
CL2019000766A
Other languages
English (en)
Inventor
Shikha P Barman
Koushik Barman
William Burns
Kathryn Crawford
Anne-Maria Cromwick
Kevin Ward
Original Assignee
Encore Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encore Vision Inc filed Critical Encore Vision Inc
Publication of CL2019000766A1 publication Critical patent/CL2019000766A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

LA PRESENTE INVENCIÓN DESCRIBE COMPOSICIONES OFTÁLMICAS DE ÉSTER DE COLINA DE ÁCIDO LIPOICO Y PROCESOS ESPECÍFICOS PARA PRODUCIR FORMULACIONES BIOCOMPATIBLES DE DICHAS COMPOSICIONES ADECUADAS PARA EL OJO.
CL2019000766A 2016-09-23 2019-03-22 Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantes. CL2019000766A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662398748P 2016-09-23 2016-09-23

Publications (1)

Publication Number Publication Date
CL2019000766A1 true CL2019000766A1 (es) 2019-08-02

Family

ID=60190904

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000766A CL2019000766A1 (es) 2016-09-23 2019-03-22 Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantes.

Country Status (19)

Country Link
US (1) US20230135366A1 (es)
EP (1) EP3515410A1 (es)
JP (1) JP7091318B2 (es)
KR (1) KR20190065304A (es)
CN (1) CN109906076A (es)
AU (1) AU2017331591B2 (es)
BR (1) BR112019005426A2 (es)
CA (1) CA3037459A1 (es)
CL (1) CL2019000766A1 (es)
CO (1) CO2019002663A2 (es)
CR (1) CR20190148A (es)
EC (1) ECSP19020167A (es)
IL (1) IL265480B (es)
JO (1) JOP20190057A1 (es)
MX (1) MX2019003365A (es)
MY (1) MY194044A (es)
PE (1) PE20191130A1 (es)
RU (1) RU2761519C2 (es)
WO (1) WO2018055572A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113387923A (zh) 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
EP4194448A4 (en) * 2020-08-27 2025-05-07 Kyowa Pharma Chemical Co., Ltd. COMPOUND OF TRISULFIDE AND CLATHRATE THEREOF
WO2023079427A1 (en) * 2021-11-03 2023-05-11 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof
CN118634218A (zh) 2023-05-24 2024-09-13 温州医科大学附属眼视光医院 一种有效延缓及治疗近视的药物组合物
CN117263907B (zh) * 2023-09-23 2026-01-27 江西科技师范大学 一种丙酮酸脱氢酶e2抑制剂及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1232539C (zh) 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
DE102004060914A1 (de) * 2004-12-17 2006-07-06 Bioghurt Biogarde Gmbh & Co. Kg Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen
EP2821405B1 (en) * 2009-06-15 2016-04-13 Encore Health, LLC Choline esters for treating presbyopia and cataract
EP3069612A3 (en) * 2009-06-15 2016-10-19 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor
CA2941518A1 (en) * 2014-03-03 2015-09-11 Encore Vision, Inc. Lipoic acid choline ester compositions and methods of use
AU2016326572B9 (en) * 2015-09-24 2019-08-08 Novartis Ag Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations

Also Published As

Publication number Publication date
AU2017331591A1 (en) 2019-04-04
IL265480A (en) 2019-05-30
JP2019534864A (ja) 2019-12-05
BR112019005426A2 (pt) 2019-06-25
CR20190148A (es) 2019-09-09
MX2019003365A (es) 2019-11-11
EP3515410A1 (en) 2019-07-31
RU2019111885A3 (es) 2020-12-21
RU2019111885A (ru) 2020-10-23
ECSP19020167A (es) 2019-07-31
CN109906076A (zh) 2019-06-18
RU2761519C2 (ru) 2021-12-09
MY194044A (en) 2022-11-09
US20230135366A1 (en) 2023-05-04
AU2017331591B2 (en) 2020-04-09
IL265480B (en) 2022-09-01
KR20190065304A (ko) 2019-06-11
JOP20190057A1 (ar) 2019-03-24
WO2018055572A1 (en) 2018-03-29
PE20191130A1 (es) 2019-09-02
CO2019002663A2 (es) 2019-06-11
CA3037459A1 (en) 2018-03-29
JP7091318B2 (ja) 2022-06-27

Similar Documents

Publication Publication Date Title
CL2019000766A1 (es) Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantes.
CL2020000946A1 (es) Métodos y composiciones para la producción de trifosfato de nucleosido y ácido ribonucleico
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
EP3694487C0 (en) Separable microneedle arrays for prolonged drug release
PL3720838T3 (pl) Sole organicznych kwasów sulfonowych i estrów aminokwasów i sposoby ich wytwarzania
MX2023006541A (es) Formulaciones de dosis fija.
EP4371616A3 (en) Compositions of obeticholic acid and methods of use
CU20190057A7 (es) Composiciones que comprenden aminoácidos
CO2018003558A2 (es) Método de cristalización y biodisponibilidad
SV2018005775A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2- carboxamida
MX384800B (es) Derivado de 3-desoxi y composiciones farmaceuticas del mismo.
MX385109B (es) Formulaciones de anticuerpos.
EP3563853A4 (en) COMPOSITION OF MANNURONDICARBONIC ACID
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
IL258258B (en) Lipoic acid choline ester preparations and methods for producing biocompatible ophthalmic formulations
HUE046850T2 (hu) Új 2' és/vagy 5' aminosav észter foszforamidát 3'-deoxi adenozin származékok mint anti-rák vegyületek
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
AR112472A1 (es) Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas
MX2017005064A (es) Metodos para tratar afecciones oculares.
BR112017008033A2 (pt) composição farmacêutica para administração oral e respectivo processo de preparação
MX2016014166A (es) Compuestos de triaminopirimidina utiles para evitar o tratar la malaria.
BR112017014085A2 (pt) processos para a preparação de hemifumarato de tenofovir alafenamida amorfo e uma pré-mistura do mesmo
MX374241B (es) Formulación de triamida fosfórica o tiofosfórica altamente concentrada.
EP3684349A4 (en) New formulation of gamma-aminobutyric acid
CO2017004382A2 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral